Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

PRELIMINARY STUDIES OF ACYCLOVIR IN CHRONIC HEPATITIS-B AMERICAN JOURNAL OF MEDICINE Smith, C. I., SCULLARD, G. H., Gregory, P. B., Robinson, W. S., Merigan, T. C. 1982; 73 (1A): 267-270

Abstract

Three patients with HBsAg-positive and DNA-polymerase-positive chronic hepatitis were treated with increasing dosages of intravenous acyclovir. A fall in DNA polymerase activity was seen with all courses of acyclovir but no dose-response relationship was evident. In only one patient did DNA polymerase fall to zero where it has remained for five months. Two out of 10 courses were associated with significant side effects with the highest dosages of acyclovir but these promptly resolved when the agent was stopped. Acyclovir's apparently partial and transient action suggests that it will not have a role in the treatment of chronic hepatitis B virus infection.

View details for Web of Science ID A1982NZ89000052

View details for PubMedID 7102705